Jinwon Life Sciences "Oral COVID-19 Treatment Global Phase 2 Clinical Trial Participant Enrollment Completed"

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 22nd that the enrollment of subjects for the global Phase 2 clinical trial of GLS-1027 (Jenuzolac), an oral COVID-19 treatment developed by the company, has been completed.

GLS-1027 is an oral low-molecular-weight immunomodulator that prevents hospitalized COVID-19 patients from progressing to severe disease. This clinical trial is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, efficacy, and dose responsiveness of orally administered GLS-1027 to prevent the worsening of symptoms to severe pneumonia in patients hospitalized with COVID-19 infection. Currently, the global Phase 2 clinical trial of GLS-1027 is underway in the United States, North Macedonia, Bulgaria, and Korea.

According to the company, the mechanism of action of GLS-1027, which suppresses the TH17 pathway related to inflammatory and autoimmune diseases, was recently published in the international journal Translational Medicine Communications. In a hamster challenge infection model that induces severe COVID-19 pneumonia, GLS-1027 dose-dependently reduced markers of pneumonia symptoms and significantly decreased virus-induced syncytia and atypia in lung tissue. This therapeutic effect was observed not only against the wild-type COVID-19 virus discovered in Wuhan but also against the Beta variant virus, which is highly resistant to vaccines.

Park Young-geun, CEO of GeneOne Life Science, stated, “By completing the enrollment of subjects for the global Phase 2 clinical trial of GLS-1027, we have achieved a very important milestone in COVID-19 treatment,” and emphasized, “We expect the clinical trial results of GLS-1027 to demonstrate its development as an effective oral treatment that can prevent lung inflammation caused by COVID-19 virus infection.”

He added, “Although we initiated subject recruitment for the Phase 2 clinical trial of GLS-1027 domestically after approval, recruitment was not successful due to various circumstances, which is regrettable,” and said, “Despite the delay in domestic subject recruitment, with the completion of enrollment overseas, we will proceed quickly with subsequent schedules and announce the clinical results.”